Related Experiment Video
Updated: Jan 13, 2026
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
Published on: October 7, 2025
AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)
Yarely M Salinas-Vera1, Laurence A Marchat2, Dolores Gallardo-Rincón3
1Posgrado en Ciencias Genomicas, Universidad Autonoma de la Ciudad de Mexico, Ciudad de Mexico 03100, Mexico.
Abstract:
Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti‑angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti‑angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non‑coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet‑derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor‑1, as well as mitogen‑activated protein kinase, phosphoinositide 3‑kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti‑angiogenic tumor therapy was explored.
Insights
MicroRNAs, or angiomiRs, are emerging as key regulators of tumor angiogenesis. Understanding their role is crucial for developing new anti-angiogenic cancer therapies to overcome treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tumor angiogenesis is critical for cancer growth and metastasis.
- Anti-angiogenic therapies are a focus for personalized cancer treatment.
- Emerging resistance to current inhibitors necessitates novel therapeutic strategies.
Purpose of the Study:
- To review the role of microRNAs (miRNAs) in regulating tumor angiogenesis.
- To explore the potential of angiomiRs as novel anti-angiogenic agents.
Main Methods:
- Literature review of current research on miRNAs and tumor angiogenesis.
- Analysis of miRNA targeting of key angiogenic molecules and pathways.
Main Results:
- MicroRNAs, termed angiomiRs, significantly influence tumor angiogenesis.
- AngiomiRs target crucial regulators like VEGF, PDGF, and FGF.
- They also impact signaling pathways including MAPK, PI3K, and TGF-β.
Conclusions:
- miRNAs play a vital role in the regulation of tumor angiogenesis across various cancers.
- AngiomiRs hold significant promise for future anti-angiogenic cancer therapies.
